RxDoctor Payments Data

Stephanie Ferrell, APRN

Family · Berea, KYNPI 1841507456

Payments from drug & device makers

$572in general payments, 2019–2025

Across 33 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ironshore Pharmaceuticals Inc.$120
  • Sunovion Pharmaceuticals Inc.$83
  • Lilly USA, LLC$53
  • Otsuka America Pharmaceutical, Inc.$39
  • Sumitomo Pharma America, Inc.$38
  • Alkermes, Inc.$36
  • plus $203 from 10 others

What the payments were for

  • Food & beverage$572100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$572 in reported general payments places this provider in the 50th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$11,463
Medicare patients
46
Services billed
144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban293$85,436
NuedextaDextromethorphan Hbr/Quinidine62$42,167
JardianceEmpagliflozin144$38,607
OzempicSemaglutide30$30,411
Risperdal ConstaRisperidone Microspheres23$26,666
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$20,977
JanuviaSitagliptin Phosphate71$20,609
TrulicityDulaglutide20$20,394
AbrysvoRsv Vacc, Pref A And Pref B/Pf64$20,063
CreonLipase/Protease/Amylase16$15,534
ErtapenemErtapenem Sodium30$14,615
XareltoRivaroxaban48$13,301
LinzessLinaclotide17$9,835
MyrbetriqMirabegron25$9,509
Spiriva HandihalerTiotropium Bromide12$6,440

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$17$38,607144 claims
GSKTrelegy Ellipta$21$20,97731 claims
Lilly USA, LLCTrulicity$53$20,39420 claims
Astellas Pharma US IncMyrbetriq$22$9,50925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,374 family providers in Kentucky.

Other family in Berea

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →